tradingkey.logo

Sol Gel Technologies Ltd

SLGL

13.400USD

+0.400+3.08%
Fechamento 08/04, 16:00ETCotações atrasadas em 15 min
37.33MValor de mercado
PerdaP/L TTM

Sol Gel Technologies Ltd

13.400

+0.400+3.08%
Mais detalhes de Sol Gel Technologies Ltd Empresa
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Informações da empresa
Código da empresaSLGL
Nome da EmpresaSol Gel Technologies Ltd
Data de listagemFeb 01, 2018
CEO- -
Número de funcionários34
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 01
EndereçoGolda Meir 7
CidadeNESS-ZIONA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal- -
Telefone97289313433
Sitehttp://www.sol-gel.com
Código da empresaSLGL
Data de listagemFeb 01, 2018
CEO- -
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 1 de ago
Atualizado em: sex, 1 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
M.Arkin Dermatology, Ltd.
64.86%
Phoenix Investment and Finances Ltd
17.73%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
Harel Insurance Investments and Financial Services Ltd
3.30%
Other
4.55%
Investidores
Investidores
Proporção
M.Arkin Dermatology, Ltd.
64.86%
Phoenix Investment and Finances Ltd
17.73%
Arkin (Moshe)
5.14%
Migdal Insurance and Financial Holdings Ltd
4.41%
Harel Insurance Investments and Financial Services Ltd
3.30%
Other
4.55%
Tipos de investidores
Investidores
Proporção
Corporation
64.86%
Investment Advisor
13.56%
Individual Investor
5.14%
Insurance Company
4.68%
Research Firm
0.60%
Venture Capital
0.08%
Hedge Fund
0.08%
Investment Advisor/Hedge Fund
0.05%
Other
10.96%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
36
2.72M
97.81%
+115.86K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
2023Q1
32
22.23M
86.47%
+2.20M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Phoenix Investment and Finances Ltd
247.02K
8.87%
--
--
Mar 31, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Migdal Insurance and Financial Holdings Ltd
122.75K
4.41%
--
--
Mar 31, 2025
Harel Insurance Investments and Financial Services Ltd
92.03K
3.3%
--
--
Mar 31, 2025
Yelin Lapidot Provident Funds Management Ltd
22.71K
0.82%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
9.24K
0.33%
+412.00
+4.67%
Mar 31, 2025
Raymond James Financial Services Advisors, Inc.
8.68K
0.31%
+311.00
+3.72%
Mar 31, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
--
--
Mar 31, 2025
BNP Paribas Securities Corp. North America
4.73K
0.17%
+780.00
+19.75%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proporção0%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI